A Simple Novel Technique to Estimate Tacrolimus Dosages During the Early Post Kidney Transplantation Period

Abstract Background Tacrolimus pharmacokinetics prediction by CYP3A5 genotyping is not available in many Asian resource-limited settings. Therefore, an alternative technique is needed to estimate the dose of tacrolimus perioperatively. The 12-hour level after the first dose (C12-0) is an alternative...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Transplantation proceedings 2015-10, Vol.47 (8), p.2433-2438
Hauptverfasser: Townamchai, N, Chancharoenthana, W, Vadcharavivad, S, Chariyavilaskul, P, Pongpirul, K, Leelahavanichkul, A, Watanatorn, S, Avihingsanon, Y, Praditpornsilpa, K, Srisawat, N
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Background Tacrolimus pharmacokinetics prediction by CYP3A5 genotyping is not available in many Asian resource-limited settings. Therefore, an alternative technique is needed to estimate the dose of tacrolimus perioperatively. The 12-hour level after the first dose (C12-0) is an alternative technique for estimating the dose of tacrolimus. This simple and inexpensive calculation technique can be used by any transplantation center. Methods A prospective study on a cohort of 57 incident post-kidney transplant recipients was conducted. The whole-blood tacrolimus trough level (C12-0) was measured at 12 hours after the first dose (0.1 mg/kg) of orally administered tacrolimus during transplantation. Concomitant medications with CYP3A5 inhibitors/inducers were not allowed. Genotyping for CYP3A5 expression was carried out by reverse transcription polymerase chain reaction. The dosages and trough levels of tacrolimus at postoperative day 7 and postoperative months 1 to 3 were measured and analyzed for the dose requirements for therapeutic levels (mg/kg/d). Results The doses of tacrolimus were widely diverse, ranging from 0.049 to 0.260 mg/kg/d and 0.031 to 0.298 mg/kg/d at day 7 and months 1 to 3, respectively. There were 9, 28, and 20 patients (15.8%, 49.1%, and 35.1%) with CYP3A5 *1/*1 , *1/*3 , and *3/*3 , respectively. The CYP3A5 genotypes were significantly correlated with the target tacrolimus dose at day 7 (r2  = 0.307) and the stable dose at months 1 to 3 (r2  = 0.337). The C12-0 level also was significantly correlated with the dose of tacrolimus at day 7 (r2  = 0.546) and the stable dose at months 1 to 3 (r2  = 0.406). Conclusions There were strong correlations between the C12-0 level and the tacrolimus doses during the perioperative period at day 7 and the stable period at 1 to 3 months. Countries with limited resources for genotype testing can use the C12-0 level as an alternative to estimate the tacrolimus dose.
ISSN:0041-1345
1873-2623
DOI:10.1016/j.transproceed.2015.08.013